Table 1

Baseline characteristics of patients according to GOLD category


Stage 0 n = 19
Stage 1 n = 9
Stage 2 n = 21
Stage 3 n = 4
Stage 4 n = 3

FEV1 (L)
2.54 (0.49)
2.06 (0.41)
1.57 (0.43)
0.96 (0.17)
0.73 (0.13)
FEV1 (%pred)
101.6 (10.1)
89.1 (11.2)
63.2 (10.3)
40.2 (7.4)
27.5 (2.3)
FVC (L)
3.39 (0.69)
3.61 (0.70)
3.38 (1.12)
3.17 (1.07)
2.83 (0.49)
FVC (%pred)
108.8 (9.6)
127.1 (22.2)
102.3 (20.4)
104.5 (14.0)
81.9 (16.4)
FEV1/FVC (%)
75.4 (6.0)
57.2 (4.5)
48.3 (10.0)
32.6 (9.5)
26.7 (7.6)
RV (L)
1.93 (0.41)
2.69 (0.56)
3.40 (0.92)
3.46 (1.02)
4.63 (1.06)
RV (%pred)
92.3 (12.7)
130.3 (24.6)
156.2 (36.5)
171.5 (34.2)
194.0 (40.5)
TLC (L)
5.44 (1.04)
6.25 (0.99)
6.59 (0.99)
6.41 (2.05)
7.01 (1.38)
TLC (%pred)
98.9 (7.9)
118.4 (12.9)
117.0 (19.3)
119.5 (17.6)
113.7 (20.5)
TLCO (mmol/min/kPa)
8.03 (2.10)
7.00 (2.28)
5.71 (2.09)
2.92 (1.18)
5.06 (1.43)
TLCO (%pred)
100.5 (21.2)
91.2 (24.3)
72.0 (21.3)
37.8 (14.8)
62.0 (13.9)
KCO (mmol/min/kPa/L)
1.60 (0.32)
1.33 (0.38)
1.14 (0.41)
0.69 (0.33)
1.14 (0.36)
KCO (%pred)
110.3 (23.4)
93.4 (31.6)
81.4 (29.2)
46.0 (20.9)
86.7 (27.5)

Figures represent the mean (standard deviation).

Parr et al. Respiratory Research 2006 7:136   doi:10.1186/1465-9921-7-136